Table 4.

Estrogen plus progestin only menopausal hormone therapy use and relative risk of lymphoid neoplasms, by type, among women with intact uteri in the NIH-AARP Diet and Health Study

Hormone therapy		No. cancers*	Person-years	RR**	95% CI	RR†	95% CI
		Plasma cell neoplasms (N=47)
No hormone therapy use		26	209,746	1.00	Ref.	1.00	Ref.
Estrogen plus progestin only		12	115,221	1.16	0.58 - 2.35	1.24	0.60 - 2.58
Recency of use
	Former	1	20,159	0.51	0.07 - 3.76	0.55	0.08 - 4.11
	Current	11	94,219	1.34	0.65 - 2.76	1.44	0.67 - 3.07
Duration of use
	<10 years	11	86,532	1.61	0.78 - 3.35	1.72	0.81 - 3.63
	>10 years	1	28,154	0.30	0.04 - 2.25	0.31	0.04 - 2.32
Regimen of estrogen plus progestin
	Sequential (<15 days)	4	41,503	1.16	0.40 - 3.37	1.21	0.39 - 3.76
	Continuous	4	22,529	1.97	0.68 - 5.70	2.13	0.72 - 6.27
		Non-Hodgkin lymphoma (N=228)
No hormone therapy use		128	210,069	1.00	Ref.	1.00	Ref.
Estrogen plus progestin only		52	115,345	0.86	0.62 - 1.20	0.84	0.60 - 1.17
Recency of use
	Former	9	20,179	0.81	0.41 - 1.61	0.80	0.41 - 1.59
	Current	43	94,322	0.88	0.62 - 1.25	0.85	0.59 - 1.23
Duration of use
	<10 years	36	86,606	0.84	0.57 - 1.23	0.82	0.56 - 1.21
	>10 years	16	28,204	0.93	0.55 - 1.56	0.89	0.52 - 1.52
Regimen of estrogen plus progestin
	Sequential (<15 days)	14	41,538	0.67	0.38 - 1.16	0.64	0.36 - 1.13
	Continuous	15	22,558	1.26	0.74 - 2.17	1.23	0.72 - 2.13
		Diffuse large B-cell lymphoma (N=52)
No hormone therapy use		26	209,754	1.00	Ref.	1.00	Ref.
Estrogen plus progestin only		11	115,226	1.07	0.52 - 2.20	1.08	0.52 - 2.27
Recency of use
	Former	2	20,164	1.02	0.24 - 4.30	1.06	0.25 - 4.48
	Current	9	94,219	1.10	0.51 - 2.37	1.10	0.49 - 2.45
Duration of use
	<10 years	7	86,527	1.02	0.43 - 2.40	1.04	0.44 - 2.48
	>10 years	4	28,164	1.19	0.41 - 3.43	1.18	0.39 - 3.51
Regimen of estrogen plus progestin
	Sequential (<15 days)	3	41,505	0.87	0.26 - 2.91	0.76	0.22 - 2.70
	Continuous	3	22,530	1.48	0.44 - 4.92	1.63	0.49 - 5.48
		Follicular lymphoma (N=62)
No hormone therapy use		35	209,775	1.00	Ref.	1.00	Ref.
Estrogen plus progestin only		15	115,234	0.82	0.44 - 1.52	0.77	0.41 - 1.46
Recency of use
	Former	3	20,163	0.92	0.28 - 3.01	0.89	0.27 - 2.93
	Current	12	94,227	0.80	0.41 - 1.57	0.75	0.38 - 1.50
Duration of use
	<10 years	12	86,539	0.90	0.46 - 1.78	0.85	0.43 - 1.68
	>10 years	3	28,160	0.62	0.19 - 2.03	0.59	0.18 - 1.95
Regimen of estrogen plus progestin
	Sequential (<15 days)	4	41,509	0.61	0.22 - 1.74	0.58	0.20 - 1.68
	Continuous	3	22,528	0.84	0.26 - 2.73	0.78	0.24 - 2.57
		CLL/SLL (N=50)
No hormone therapy use		27	209,743	1.00	Ref.	1.00	Ref.
Estrogen plus progestin only		12	115,232	0.89	0.45 - 1.80	0.86	0.42 - 1.75
Recency of use
	Former	1	20,160	0.41	0.06 - 3.00	0.40	0.05 - 2.96
	Current	11	94,229	1.02	0.50 - 2.09	0.97	0.46 - 2.04
Duration of use
	<10 years	8	86,528	0.83	0.37 - 1.87	0.80	0.35 - 1.83
	>10 years	4	28,169	1.07	0.37 - 3.06	1.01	0.34 - 2.97
Regimen of estrogen plus progestin
	Sequential (<15 days)	2	41,506	0.43	0.10 - 1.81	0.41	0.09 - 1.78
	Continuous	4	22,530	1.51	0.52 - 4.35	1.41	0.48 - 4.14

Abbreviations: chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL); relative risk (RR).

^*No. cancers may not sum to total due to use of other hormone therapy formulations or missing data.

^**RRs adjusted for age (continuous) and other hormone therapy formulations.

^†RRs adjusted for age (continuous), race, menopausal status, oral contraceptive use, education, smoking status, and other hormone therapy formulations.